DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-263/S-020

TAP Pharmaceutical Products, Inc.
Attention: Jessie Lee, PhD, RAC
Senior Regulatory Product Manager
675 North Field Drive
Lake Forest, IL 60045

Dear Dr. Lee:

Please refer to your supplemental new drug application dated May 21, 2002, received May 24, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lupron PED (leuprolide acetate/injection/depot suspension).

We acknowledge receipt of your submissions dated July 18 and August 12, 2002.

This supplemental new drug application provides for the addition of a syringe safety needle guard, LuproLoc™, to the prefilled dual-chamber syringe (PDS) system used in the Lupron Depot syringe products.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text, with one revision. The "Rx" symbol of the package insert should be immediately above the DESCRIPTION section. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling (package insert, patient package and immediate container and carton labels submitted May 21, 2002) with the revision noted above.

Please submit the copies of final printed labeling (FPL) electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-263/S-020." Approval of this submission by FDA is not required before the labeling is used.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Monika Johnson, PharmD, Regulatory Project Manager at (301) 827-6370.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

David Orloff

9/24/02 12:11:57 PM